Mylan wins motion to enjoin GSK from providing paroxetine CR to Apotex
US generics drug major Mylan (Nasdaq: MYL) says that the US District Court for the District of New Jersey granted its motion for a permanent injunction against UK pharma major GlaxoSmithKline (LSE: GSK) in relation to paroxetine CR, the generic version of GSK's antidepressant Paxil CR.
GSK is now precluded from supplying product to Canada-headquartered generics firm Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106.7 million by the District Court after a favorable jury verdict in March 2014.
In addition, the District Court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since September 30 as a result of GSK's ongoing breach. All of GSK's post-trial motions were denied.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze